Alterations in cancer genomes strongly influence clinical responses to treatment and in many
instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in …

Clinical responses to anticancer therapies are often restricted to a subset of patients. In some
cases, mutated cancer genes are potent biomarkers for responses to targeted agents. Here…

Systematic studies of cancer genomes have provided unprecedented insights into the
molecular nature of cancer. Using this information to guide the development and application of …

K-ras mutations occur frequently in epithelial cancers. Using short hairpin RNAs to deplete K-Ras
in lung and pancreatic cancer cell lines harboring K-ras mutations, two classes were …

Targeted cancer therapies have produced substantial clinical responses, but most tumors
develop resistance to these drugs. Here, we describe a pharmacogenomic platform that …

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly
for hematologic malignancies. To date, however, genomic biomarkers to direct clinical …

Selective kinase inhibitors have had a substantial impact on the field of medical oncology.
Whereas these agents can elicit dramatic clinical responses in some settings, their activity is …

KRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for
KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy to identify …

Kinase inhibitors constitute an important new class of cancer drugs, whose selective
efficacy is largely determined by underlying tumor cell genetics. We established a high-throughput …

AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid
commitment to apoptosis in models of hematologic malignancies. The synergistic …